Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA-Reference-Cited by-同舟云学术

Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA

Published:2022-08 Issue:11 Volume:11 Page:815-828
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Engelbrecht Kayla¹^ORCID,Roy Srinjoy²^ORCID,Capkun Gorana³^ORCID,Kahler Kristijan⁴^ORCID,Olson Melvin⁵^ORCID

Affiliation:

1. RWE Specialist, Real World Evidence, CTS CONEXTS, Novartis Pharmaceuticals UK Ltd, London, W12 7FQ, UK

2. RWE Scientific Data Analyst, Real World Evidence, Novartis Healthcare Private Limited, Salarpuria-Sattva Knowledge City, Raidurg, Rangareddy District, Madhapur/Hyderabad, 500081, Telangana

3. Global Head RWD Analytics & Evidence Enablement, Novartis Oncology, Basel, 4056, Switzerland

4. Global Head External Data Partnerships, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

5. Global Head of Integrated Evidence Strategy & Innovation, Global Medical Affairs, Novartis Pharma AG, Basel, 4056, Switzerland

Abstract

Aim: To analyze the impact of the COVID-19 pandemic on US healthcare resource utilization. Methods: Optum claims data were used to compare all-cause healthcare visits and healthcare spending for selected diseases between the prepandemic and pandemic periods. Telemedicine use was only assessed for the pandemic period owing to data availability. Results: During the first wave of the pandemic, all-cause healthcare visits across all selected disease areas displayed a rapid decline compared with the prepandemic period, followed by a period of recovery. A reduction in outpatient and home healthcare spending was observed, whereas inpatient and prescription spending increased. Conclusion: Changes in healthcare resource utilization trends were observed during the pandemic. The magnitude of these changes can inform subsequent studies that utilize COVID-19-era data.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.2217/cer-2022-0059

Reference34 articles.

1. World Health Organization. WHO Director-General’s Statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV) (2021). www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)

2. World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 – 11 March 2020 (2021). www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard (2021). https://covid19.who.int/

4. Congress.gov. H.R.6074 – Coronavirus Preparedness and Response Supplemental Appropriations Act 2020. (2020). www.congress.gov/bill/116th-congress/house-bill/6074

5. Congress.gov. H.R.3103 – Health Insurance Portability and Accountability Act of 1996:104th Congress (1995–1996). (1996). www.congress.gov/bill/104th-congress/house-bill/3103

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Lab Findings in Predicting COVID-19 Outcomes in Older Adults;2023-12-06

2. Association between the Demographic Characteristics, Severity, Clinical Symptoms, Vital Signs, and Lab Findings and COVID-19 Outcomes in Older Adults;2023-11-29

3. Association between the Demographic Characteristics, Severity, Clinical Symptoms, Vital Signs, Lab Findings with COVID-19 Outcomes in Older Adults;2023-11-28

4. Association between the Demographic Characteristics, Severity, Clinical Symptoms, Vital Signs, Lab Findings with COVID-19 Outcomes in Older Adults;2023-11-27

5. Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic;JNCI: Journal of the National Cancer Institute;2023-10-05